欣维宁对ST段抬高性急性心肌梗死冠脉内血栓的影响

目的探讨欣维宁治疗ST段抬高性急性心肌梗死（AMI）的有效性与安全性及对冠脉内血栓的影响。方法治疗组的18例ST段抬高性AMI患者均有行急诊介入治疗的适应症，冠脉造影显示冠脉内血栓形成，行经皮冠状动脉介入治疗术（PCI）后血栓未能消失，远端TIMI血流1级或以下，对照组为前期本科未开展急诊介入治疗前有行急诊介入治疗的适应症且未溶栓患者，满2周后择期行冠脉造影（20例），比较两组患者出现心衰、休克或死亡等心脏不良事件、冠脉内血栓及远端血流情况。结果出现心衰、休克或死亡等心脏不良事件治疗组（5．6％）较对照组（40％）明显减低，2周后造影显示治疗组及对照组犯罪血管血栓发生率分别为5．6％及35％，治疗组及对照组TIMI血流2级或以上分别为88．9％及45％，差异均有显著性。出血并发症治疗组（16．7％），高于对照组（5％），比较差异无显著性（P值〉0．05），两组均无肝肾功能损害及其他不良反应。结论欣维宁能消除冠脉内血栓、改善心肌灌注、减少主要心脏不良事件发生，疗效确切，安全性好。

The influence of coronary thrombosis in patients with ST elevation acute myocardial infarction treated by tirofiban

Objective To investigate the efficacy and safety in the treatment with tirofiban in patients with ST elevation acute myocardial infarction and its influence on the coronary thrombosis.Methods 18 patients in the treatment group were patients with ST elevation acute myocardial infarction treated by emergency interventional therapy whose coronary angiography showed coronary thrombosis and the thrombosis could not disappear after the PCI.The remote flow of TIMI was only 1 or less.20 patients in the control grou...